Zentalis Pharmaceuticals, Inc. $ZNTL Shares Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP increased its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 188.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 317,600 shares of the company’s stock after buying an additional 207,600 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Zentalis Pharmaceuticals were worth $1,451,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. 5AM Venture Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at $19,147,378,000. BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter worth about $18,205,000. Millennium Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares in the last quarter. Ishara Investments LP acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $1,782,000. Finally, Bank of America Corp DE acquired a new position in Zentalis Pharmaceuticals during the second quarter worth $5,406,000.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZNTL. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.75.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.80% of the company’s stock.

Zentalis Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:ZNTL opened at $3.89 on Thursday. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.21 and a 12 month high of $6.95. The firm has a market cap of $278.80 million, a P/E ratio of -1.99 and a beta of 1.92. The company’s 50-day moving average price is $4.36 and its two-hundred day moving average price is $3.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.